The results of this meta-analysis indicate that pramlintide supplement as an adjunct to insulin therapy might improve glycemic control and reduce body weight and insulin dose while bring transient hypoglycemia and digestive disorders in patients with type 1 diabetes. The gene discussed is INS; the disease is type 1 diabetes mellitus.